Patent intelligence · AT
AT E191006
MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN RHESUS D UND ZELLINIEN DIE DIESE PRODUZIEREN
MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN RHESUS D UND ZELLINIEN DIE DIESE PRODUZIEREN
Patent details — AT E191006
- Jurisdiction
- AT
- Status
- expired
- Grant date
- Apr 15, 2000
- Expiration
- Apr 10, 2020
- Applicant
- AETSRN [FR]
- CPC classes
- A61K 39/ 395 A I, A61K39/395
Quick answer
AT E191006 (MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN RHESUS D UND ZELLINIEN DIE DIESE PRODUZIEREN) is held by AETSRN [FR]. Status: expired. Granted Apr 15, 2000. Expires Apr 10, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AETSRN [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K39/395
More from AETSRN [FR]
Related pharmaceutical patents in our USPTO index.
-
CA 1341505
PREPARATION D'IMMUNOGLOBULINE POLYCLONALE CONTENANT DE L'IGM, AUX FINS D'ADMINISTRATION INTRAVEINEUSE, AINSI QUE SA METHODE DE FABRICATION
expired -
DK 0781560
Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse
expired -
DE 69229278
HUMANISIERTER B-B10, EIN ANTI-IL-2-REZEPTOR-ANTIKÖRPER
expired
Frequently asked questions
What is US patent E191006?
AT E191006 (MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN RHESUS D UND ZELLINIEN DIE DIESE PRODUZIEREN) is held by AETSRN [FR]. Status: expired. Granted Apr 15, 2000. Expires Apr 10, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AT E191006?
AETSRN [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does AT E191006 expire?
Our index shows an expiration date of Apr 10, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.